Skip to main content

Table 2 Adverse events during the 12 weeks

From: Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent

Variables, n (%)

Vildagliptin (n = 166)

Sitagliptin (n = 165)

Linagliptin (n = 164)

χ2 values

P values

Hypoglycemia

20 (12.05)

17 (10.30)

13 (7.29)

1.554

0.460

Gastrointestinal adverse events

24 (14.46)

19 (11.52)

15 (9.15)

2.260

0.323

Renal and hepatic toxicity

6 (3.61)

5 (3.30)

2 (1.22)

2.008

0.366

Infections

10 (6.02)

8 (4.85)

12 (7.32)

0.881

0.644

Chest discomfort

8 (4.82)

11 (6.70)

11 (6.71)

0.676

0.713